CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 98 filers reported holding CYTOSORBENTS CORP in Q1 2021. The put-call ratio across all filers is 2.28 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $6,810 | -94.7% | 1,897 | -95.3% | 0.00% | – |
Q1 2022 | $128,000 | -23.8% | 40,176 | -0.0% | 0.00% | – |
Q4 2021 | $168,000 | -49.4% | 40,192 | -1.6% | 0.00% | – |
Q3 2021 | $332,000 | +8.9% | 40,852 | +1.1% | 0.00% | – |
Q2 2021 | $305,000 | -17.3% | 40,427 | -5.0% | 0.00% | -100.0% |
Q1 2021 | $369,000 | +3.1% | 42,558 | -5.3% | 0.00% | – |
Q4 2020 | $358,000 | +11.9% | 44,923 | +11.8% | 0.00% | -100.0% |
Q3 2020 | $320,000 | -26.9% | 40,171 | -9.1% | 0.00% | 0.0% |
Q2 2020 | $438,000 | +46.5% | 44,211 | +14.1% | 0.00% | 0.0% |
Q1 2020 | $299,000 | +100.7% | 38,734 | 0.0% | 0.00% | – |
Q4 2019 | $149,000 | -23.2% | 38,734 | +0.5% | 0.00% | – |
Q3 2019 | $194,000 | -24.5% | 38,527 | -0.8% | 0.00% | – |
Q2 2019 | $257,000 | -20.2% | 38,827 | -8.8% | 0.00% | -100.0% |
Q1 2019 | $322,000 | +4.5% | 42,589 | +11.7% | 0.00% | 0.0% |
Q4 2018 | $308,000 | -3.1% | 38,135 | +54.8% | 0.00% | 0.0% |
Q3 2018 | $318,000 | +7.8% | 24,630 | -4.8% | 0.00% | 0.0% |
Q2 2018 | $295,000 | – | 25,881 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 450,000 | $846,000 | 0.90% |
Skylands Capital, LLC | 2,944,670 | $5,535,980 | 0.84% |
Sargent Investment Group, LLC | 1,257,048 | $2,363,250 | 0.57% |
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 197,940 | $372,127 | 0.52% |
Avenir Corp | 2,717,397 | $5,108,706 | 0.48% |
Granahan Investment Management | 1,552,393 | $2,918,499 | 0.10% |
Seelaus Asset Management LLC | 20,450 | $38,446 | 0.04% |
HighMark Wealth Management LLC | 10,000 | $18,800 | 0.02% |
Key Client Fiduciary Advisors, LLC | 13,000 | $24,440 | 0.02% |
Eudaimonia Partners, LLC | 23,500 | $44,180 | 0.01% |